OncLive SOSS

Authors

Insight From: Cathy Eng, MD, MD Anderson&nbsp

Insight From: Cathy Eng, MD, MD Anderson Jessica Mitchell, RN, CNP, MPH Mayo&nbsp

Insight From: Cathy Eng, MD, MD AndersonÂ

Insight From: Ezra Cohen, MD, UCSD

Insight From: Joanne L. Blum, MD, PhD, Texas Oncology

Insight from: John Sweetenham, MD, Huntsman

Insight From: Noopur Raje, MD, Dana-Farber

Insight From: Primo N. Lara, Jr, MD, UC Davis

Insight From: Robert L. Ferris, MD, PhD, Pittsburgh

Insights from: Wells A. Messersmith, MD, FACP, University of Colorado Cancer Center

Ira M. Klein, MD, MBA

Latest:

Oncology Enters the Informatics Era: Many Eager to Jump on the Health Information Highway

The unifying principle for care delivery in every situation should ideally be centered on complete clinical information, coupled with evidence-based medicine, and filtered through clinical decision support tools.

Ira Winer, MD, PhD

Latest:

Dr. Winer on the Tolerability of ALKS 4230 Plus Pembrolizumab in Ovarian Cancer

Ira Winer, MD, PhD, discusses the tolerability of ALKS 4230 plus pembrolizumab in ovarian cancer.

Latest:

Dr. Ghobrial on Antibodies for Multiple Myeloma Treatment

Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the use of monoclonal antibodies for the treatment of multiple myeloma.

Irene Ghobrial, MD

Latest:

Disparities in Multiple Myeloma Care: The Path Toward Health Equity

Expert panelists share their closing thoughts on the path to improve health equity in multiple myeloma management for racial and ethnic minority groups.

Isaac Perlmutter Cancer Center

Isabel Preeshagul, DO, MBS

Latest:

Lung Cancer State of the Science Summit Recap | Chaired by: Isabel Preeshagul, DO, MBS

Isabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.

Isabella C. Glitza, MD

Latest:

Dr. Glitza on Intrathecal Nivolumab Approaches in Leptomeningeal Disease

Isabella C. Glitza, MD, discusses a single-center phase I/Ib trial of concurrent intravenous and intrathecal nivolumab for patients with metastatic melanoma and leptomeningeal disease.

Ismail Baris Turkbey, MD

Latest:

Dr. Turkbey on Sodium Fluoride PET Imaging for Prostate Cancer

Ismail Baris Turkbey, MD, staff clinician in the Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, discusses sodium fluoride PET imaging for patients with prostate cancer.

Istvan Pataki, MD

Latest:

Voice Recognition Systems Save Time and Money

Due to a variety of factors, today’s oncologists face multiple challenges in collecting, managing, and sharing their patients’ health data.